Veri
Medtech (VRHI) Files Registration Statement for Proposed Initial Public
Offering
NEW
YORK, NY – November 17, 2025 – OTC Markets -- Veri Medtech Holdings, Inc. (Stock
Ticker Symbol: “VRHI”) ("Veri Medtech"), healthcare technology
platform, announced today that it has filed a registration statement on Form
S-1 with the U.S. Securities and Exchange Commission (SEC) relating to a
proposed initial public offering of its Class A common stock. The number of
shares to be offered and the price range for the proposed offering have not yet
been determined. The offering is subject to market conditions, and there can be
no assurance as to whether or when the offering may be completed, or as to the
actual size or terms of the offering. The
proposed offering will be made only by means of a prospectus. A registration
statement relating to these securities has been filed with the SEC but has not
yet become effective. These securities may not be sold, nor may offers to buy
be accepted, prior to the time the registration statement becomes effective.
Company
Information: The information provided on the
company’s website, press releases, in related materials, and in any documents
or communications distributed by Veri Medtech Holdings, Inc. (the “Company”) is
for informational purposes only. Company
information does not constitute an offer or solicitation to sell shares or
securities in the Company or any related or associated entity. Any such offer or solicitation will be made
solely through a Company offering memorandum or similar formal investment documentation,
in strict accordance with the terms of all applicable securities laws and
regulations.
No
information, statements, or analyses presented on this site, on the Company’s
website, or in any Company media, or in Company materials, are intended to form
the basis of any investment decision, nor do they constitute investment advice,
recommendations, or counsel. This material does not constitute or form part of
— and should not be construed as — any offer for sale or subscription, or any
invitation to offer to buy or subscribe for any securities, nor should it or
any part of it form the basis of, or be relied upon in connection with, any
contract or commitment of any kind. The
Company expressly disclaims any and all liability for any direct or
consequential loss or damage arising directly or indirectly from: (i) reliance
on any information provided here or in related materials; (ii) any error,
omission, or inaccuracy in such information; or (iii) any action taken or
decision made based on such information.
Forward
Looking Statements:
Cautionary Note Regarding Forward-Looking Statements: This press release
contains statements, which may constitute "forward-looking
statements" within the meaning of the Securities Act of 1933 and the
Securities Exchange Act of 1934, as amended by the Private Securities
Litigation Reform Act of 1995. Those statements include statements regarding
the intent, belief or current expectations of Veri Medtech (OTC:
"VRHI") and members of its management as well as the assumptions on which
such statements are based. Prospective investors are cautioned that any such
forward-looking statements are not guarantees of future performance and involve
risks and uncertainties, and that actual results may differ materially from
those contemplated by such forward-looking statements.
About
Veri Medtech (OTC Markets: VRHI):
Veri Medtech is a publicly-traded healthcare technology company that offers
alternative medicine, personalized diagnostics, and wellness medication on
demand. The company leverages telehealth infrastructure, diagnostic
intelligence, and scalable digital systems to meet the growing demand for
accessible, stigma-free healthcare. Strategically positioned for growth, Veri
MedTech actively explores acquisitions that complement its core capabilities
and enhance patient engagement across emerging sectors of alternative medicine,
longevity, and wellness science. With a strong integration and operational
efficiency track record, the company drives accelerated revenue through the
continuous generation of high-value patient databases and recurring service
models. With a commitment to innovation and patient-centric care, Veri MedTech
continues to expand its services and reach, aiming to make personalized
healthcare more accessible and effective for all. For more information, please
visit: www.VeriMedTech.com
About
Veriheal: Veriheal,
a wholly-owned subsidiary of publicly-traded Veri Medtech Holdings - OTC
Markets (“VRHI”), is a healthcare technology company on a mission to help
people gain access to alternative medicine treatments. For more
information, please visit: www.Veriheal.com
About
DosePop: DosePop,
a wholly-owned subsidiary of publicly-traded Veri Medtech Holdings - OTC
Markets (“VRHI”), provides a one-stop healthcare technology platform for mental
and physical health, all designed to empower you to take charge of your
well-being. From weight loss solutions to anti-aging, our treatments are backed
by science and administered by licensed professionals. For more information,
please visit: www.DosePop.com
About
Global Telemedicine:
The global telemedicine
market size was valued at USD 114.98 billion in
2023 and is expected to grow at a compound annual growth rate (CAGR) of 17.96%
from 2024 to 2030. Telemedicine market growth is being driven by factors
such as consolidation across industry, strategic initiatives by key companies,
and increasing healthcare consumerism. Furthermore, rising adoption of
telemedicine by providers, increasing patient acceptance and consumer demand,
and delivery of improved quality of care are expected to contribute to the
growth of the telemedicine market over the forecast period. For instance, in
May 2021, Walmart Inc. acquired a telehealth company, MeMD. This acquisition is
expected to enable Walmart to expand its offerings and provide virtual access
to primary, urgent, and behavioral healthcare services nationwide. Source:
Grandview Research. https://www.grandviewresearch.com/industry-analysis/telemedicine-industry
Google Übersetzer
